Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

Abstract

This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.